Education
About Us
Working with TipRanks
Follow Us
Bio-Rad Laboratories (BIO)
:BIO
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
1.84Last Year’s EPS
3.11Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 01, 2025
|% Change Since: -1.70%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Neutral
The earnings call detailed both positive developments, such as the outperformance of the Clinical Diagnostics business, product innovations, and strong free cash flow, alongside significant challenges, including a decline in revenue, softness in the Life Science segment, and impacts from tariffs and macroeconomic conditions. The sentiment of the call is balanced with notable achievements and substantial challenges.Company Guidance
During the Bio-Rad first-quarter 2025 earnings call, the company provided guidance reflecting both achievements and ongoing challenges. Bio-Rad reported Q1 revenue of approximately $585 million, a 4.2% decline from the previous year on a reported basis, with a 1.5% decrease on a currency-neutral basis. The Life Science Group experienced a 5.4% drop in sales, primarily due to softness in the biotech and academic research markets, while the Clinical Diagnostics Group saw a 3.2% decline. Despite these declines, the Process Chromatography business experienced mid-teens growth year-over-year, and the company maintained strong demand for consumables. The company updated its 2025 full-year guidance to reflect these results and the current macroeconomic environment, anticipating total currency-neutral revenue to range from a 1% decline to 1.5% growth. Challenges such as softer academic research funding and the impact of tariffs were considered, with tariffs alone representing a 130 basis points headwind to the operating margin. Despite these headwinds, the company remains focused on operational efficiency and expects non-GAAP operating margins to be between 10% and 12% for the year. Additionally, Bio-Rad aims for a full-year free cash flow target of approximately $310 million to $330 million, with plans to continue share repurchases and strategic investments.Clinical Diagnostics Business Outperformance
The Clinical Diagnostics business performed slightly better than forecast despite reimbursement reductions in China, with nearly 3% growth in the rest of the world.
Process Chromatography Business Growth
The process chromatography business experienced mid-teens growth on a year-over-year basis, contributing positively to the Life Science segment.
Product Innovation and Expansion
Bio-Rad launched several key menu expansions for their life science portfolio, including a new PCR-based salmonella test for food safety and advances in ddPCR Vericheck assays for cell and gene therapy.
Stilla Technologies Acquisition on Track
The acquisition of Stilla Technologies is on track for closing by the end of the third quarter, which will expand Bio-Rad's offering in the digital PCR segment.
Strong Free Cash Flow
For Q1 2025, Bio-Rad reported free cash flow of $96 million, compared to $30 million in Q1 2024.
---
BIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
BIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| May 01, 2025 | $240.43 | $236.34 | -1.70% |
| Feb 13, 2025 | $306.36 | $277.16 | -9.53% |
| Oct 30, 2024 | $330.58 | $358.19 | +8.35% |
| Aug 01, 2024 | $341.25 | $335.93 | -1.56% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Bio-Rad Laboratories (BIO) report earnings?
Bio-Rad Laboratories (BIO) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is Bio-Rad Laboratories (BIO) earnings time?
Bio-Rad Laboratories (BIO) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BIO EPS forecast?
BIO EPS forecast for the fiscal quarter 2025 (Q2) is 1.84.
---